Market LIVE
Published markets; coverage varies by country
Product profile · United States

TYRVAYA

 ·  Patent Litigation & Settlement History ↓

IngredientVARENICLINE TARTRATE
Application typeNDA
Application213978
Product001
Dosage formSPRAY
RouteNASAL
StrengthEQ 0.03MG BASE/SPRAY
Approval date2021-10-15
Marketing statusPrescription
Status event—
ApplicantOYSTER POINT PHARMA
Product source

Current GenericRadar decision

Year2035
SelectionCANDIDATE
ReviewFINAL_CHECKING
Anchor typeDS_EQUIVALENT
Anchor date2035-10-19
Patent anchor2035-10-19
Exclusivity anchor2024-10-15
Protection date—
First Final ANDA—
Status event—

GNR judgment: CANDIDATE. Reference year: 2035. Anchor type: DS_EQUIVALENT. Patent anchor: 2035-10-19. Exclusivity anchor: 2024-10-15. Anchor date: 2035-10-19. Patent tail: no. Exclusivity tail: no. Review status: FINAL_CHECKING. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
104563962035-10-19DP/U U-1900———
———
112245982035-10-19U U-1900———
———
119039412035-10-19U U-1900———
———
119039422035-10-19DP ————
———
119039432035-10-19U U-1900———
———
119113802035-10-19U U-1900———
———
125760802035-10-19U U-1900———
———
126538242035-10-19DP ————
———
95046442035-10-19U U-1900———
———
95046452035-10-19DP ————
———
95329442035-10-19U U-1900———
———
95972842035-10-19U U-1900———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NP—2024-10-15Historical Orange Book exclusivity; scope and start date not independently established————Source

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

Event datePartyEvent Licensed entryEvidenceSource
Not disclosed Undisclosed generic company SETTLEMENT 2034-10 REVIEW —
Counterparty undisclosed